Bezlotoxumab

DRUG9 trials

Conditions

C. Diff. InfectionsClostridia Difficile ColitisClostridioides DifficileClostridioides Difficile InfectionClostridioides Difficile Infection RecurrenceClostridium DifficileClostridium Difficile InfectionClostridium Difficile Infection Recurrence

Phase 2

ICON-2: FMT and Bezlotoxumab Compared to FMT and Placebo for Patients With IBD and CDI

CompletedNCT03829475

Brigham and Women's HospitalClostridium Difficile Infection, Inflammatory Bowel Diseases

Start: 2020-01-01End: 2025-06-01Updated: 2025-12-09

Bezlotoxumab Yielded Outcomes by Addressing Personalized Needs in Clostridioides Difficile Infection

CompletedNCT05304715

Hellenic Institute for the Study of SepsisClostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Mortality +2

Start: 2022-04-13End: 2023-06-04Updated: 2026-03-04

Phase 3

Bezlotoxumab (MK-6072) Versus Placebo in Children With Clostridium Difficile Infection (CDI) (MK-6072-001)

CompletedNCT03182907

Merck Sharp & Dohme LLCClostridium Difficile Infection

Start: 2018-03-27End: 2022-05-12Updated: 2023-07-27

Phase 4

Comparing the Effectiveness of IV Bezlotoxumab Versus Placebo in Decreasing Morbidity and Mortality in Patients With Fulminant C. Diff Requiring Surgery.

TerminatedNCT03756454

Michael E Villarreal, MDClostridia Difficile Colitis, Clostridium; Sepsis

Start: 2019-08-19End: 2022-05-23Updated: 2023-05-12

Bezlotoxumab (BEZLO) In Addition To Standard Of Care (SOC) Vancomycin For The Treatment of Multi-Recurrent Clostridium Difficile Infection

CompletedNCT03880539

University of Kansas Medical CenterClostridium Difficile Infection Recurrence

Start: 2019-06-25End: 2021-11-18Updated: 2022-05-26

Bezlotoxumab as Secondary Prophylaxis for C. Difficile in High-risk Hospitalized Patients Exposed to Antibiotics.

TerminatedNCT03937999

Montefiore Medical CenterClostridium Difficile

Start: 2019-08-30End: 2022-05-15Updated: 2022-11-09

Prevention of Recurrent Clostridium Difficile Infection (CDI) in Patients With Inflammatory Bowel Disease (IBD).

TerminatedNCT04626947

David Binion, MDC. Diff. Infections, Crohn Disease, Inflammatory Bowel Diseases +1

Start: 2021-10-14End: 2024-05-31Updated: 2025-06-05

Bezlotoxumab Versus FMT for Multiple Recurrent CDI

WithdrawnNCT05077085

Leiden University Medical CenterClostridioides Difficile, Clostridium Infections, Enterocolitis, Pseudomembranous

Start: 2022-01-31End: 2024-12-31Updated: 2023-03-28

Unknown Phase

Real-world Evaluation of Bezlotoxumab for the Management of Clostridioides Difficile Infection

CompletedNCT04317963

University of Illinois at ChicagoClostridium Difficile Infection, Clostridium Difficile Infection Recurrence

Start: 2020-02-12End: 2023-02-22Updated: 2023-02-28

2026-01-02

Double-Blind, Placebo-Controlled Study of Bezlotoxumab in Children Receiving Antibacterial Treatment for <i>Clostridioides difficile</i> Infection (MODIFY III)

Journal of the Pediatric Infectious Diseases Society2023-06-0112 citations